39743-20-9

Basic information

• Product Name: 1-(3-CHLOROPROPYL)-PYRROLIDINE
• Synonyms: N-CHLOROPROPYL PYRROLIDINE;Albb-007086;(3-Chloropropyl)pyrrolidine, HCl;Pyrrolidine,1-(3-chloropropyl)-;1-(3-CHLOROPROPYL)-PYRROLIDINE
• CAS NO: 39743-20-9
• Molecular Formula: C₇H₁₄ClN
• Molecular Weight: 147.65
• Mol File: 39743-20-9.mol

Chemical Properties

• Boiling Point: 194.5 °C at 760 mmHg
• Flash Point: 71.4 °C
• Appearance: /
• Density: 1.016 g/cm³
• Vapor Pressure: 0.44mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 10.10±0.20(Predicted)
• CAS DataBase Reference: 1-(3-CHLOROPROPYL)-PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-CHLOROPROPYL)-PYRROLIDINE(39743-20-9)
• EPA Substance Registry System: 1-(3-CHLOROPROPYL)-PYRROLIDINE(39743-20-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 39743-20-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-(3-CHLOROPROPYL)-PYRROLIDINE is used as a building block for the synthesis of pharmaceutical intermediates, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemicals:
1-(3-CHLOROPROPYL)-PYRROLIDINE is utilized in the production of agrochemicals, serving as a key component in the synthesis of various agricultural chemicals that aid in crop protection and enhancement of agricultural productivity.
Used in Organic Synthesis:
1-(3-CHLOROPROPYL)-PYRROLIDINE is employed as a reagent in organic synthesis, enabling the creation of a wide range of organic compounds for diverse applications across different industries.
Safety Considerations:
Due to its classification as a hazardous chemical, 1-(3-CHLOROPROPYL)-PYRROLIDINE should be handled with caution, preferably in a controlled laboratory environment to ensure safety and minimize potential risks.

InChI:InChI=1/C7H14ClN/c8-4-3-7-9-5-1-2-6-9/h1-7H2

Upstream product

• 57616-69-0 1-(3-chloropropyl)pyrrolidine hydrochloride 
• 19748-66-4 3-pyrrolidin-1-yl-propan-1-ol 
• 123-75-1 pyrrolidine 
• 109-70-6 1.3-chlorobromopropane 

Downstream Products

• 3733-37-7 10-(3-pyrrolidin-1-yl-propyl)-10H-phenothiazine 
• 3810-87-5 2-chloro-10-(3-pyrrolidin-1-yl-propyl)-10H-phenothiazine 
• 112972-12-0 2,2-diphenyl-5-pyrrolidino-valeronitrile; hydrochloride 
• 36978-99-1 2-methoxy-10-(3-pyrrolidino-propyl)-phenothiazine 
• 102021-80-7 3,4,5-trimethoxy-trans-cinnamic acid-(3-pyrrolidino-propyl ester) 
• 76277-39-9 2-(3-pyrrolidinylpropyl)-1H-isoindole-1,3(2H)-dione 
• 101085-07-8 2-(3-pyrrolidino-propylamino)-ethanol 
• 29981-29-1 5-methyl-11-(3-pyrrolidin-1-yl-propyl)-5,11-dihydro-dibenzo[b,e][1,4]thiazepine 
• 67466-11-9 10-(3-pyrrolidin-1-yl-propyl)-10H-benzo[b]pyrido[2,3-e][1,4]thiazine 
• 46885-35-2 5-(3-pyrrolidin-1-yl-propyl)-5H-thieno[2,3-d]pyridazin-4-one 
• 46885-36-3 6-(3-pyrrolidin-1-yl-propyl)-6H-thieno[2,3-d]pyridazin-7-one 
• 46966-87-4 4-chloro-2-(3-pyrrolidin-1-yl-propyl)-2H-thieno[3,4-d]pyridazin-1-one 
• 97018-02-5 2-ethyl-10-(3-pyrrolidin-1-yl-propyl)-10H-phenoxazine 
• 54719-98-1 2-nitro-10-(3-pyrrolidin-1-yl-propyl)-10H-dibenzo[b,f][1,4]oxazepin-11-one 

Relevant articles and documents

Multifunctional cholinesterase inhibitors for Alzheimer's disease: Synthesis, biological evaluations, and docking studies of o/p-propoxyphenylsubstituted-1H-benzimidazole derivatives

This study indicates the synthesis, cholinesterase (ChE) inhibitory activity, and molecular modeling studies of 48 compounds as o- and p-(3-substitutedethoxyphenyl)-1H-benzimidazole derivatives. According to the ChE inhibitor activity results, generally, para series are more active against acetylcholinesterase (AChE) whereas ortho series are more active against butyrylcholinesterase (BuChE). The most active compounds against AChE and BuChE are compounds A12 and B14 with IC50 values of 0.14 and 0.22 μM, respectively. Additionally, the most active 16 compounds against AChE/BuChE were chosen to investigate the neuroprotective effects, and the results indicated that most of the compounds have free radical scavenging properties and show their effects by reducing free radical production; moreover, some of the compounds significantly increased the viability of SH-SY5Y cells exposed to H2O2. Overall, compounds A12 and B14 with potential AChE and BuChE inhibitory activities, high neuroprotection against H2O2-induced toxicity, free radical scavenging properties, and metal chelating abilities may be considered as lead molecules for the development of multi-target-directed ligands against Alzheimer's disease.

west Neeb salt and its crystalline form, and its preparation method and pharmaceutical composition (by machine translation)

The invention relates to west Neeb salt and its crystalline form, compared with the prior art, and its west Neeb salt of the invention the crystalline form has more excellent in water solubility. The present invention also relates to the west states the Neeb salt and its crystal preparation method, the medicament composition and its use in treating and/or preventing the pathological angiogenic diseases use of the medicament. (by machine translation)

Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands

Sigma 1 receptors are associated with neurodegenerative and psychiatric disorders. These receptors, via their chaperoning functions that counteract endoplasmic reticulum stress and block neurodegeneration, may serve as a target for a new generation of antidepressants or neuroprotective agents. The involvement of these receptors has also been observed in neuropathic pain and cancer. Only a few ligands, such as Igmesine and Anavex 2-73, have been involved in clinical trials. Thus the development of sigma 1 ligands is of interest to a new generation of drugs. Previous work in our lab underlined the potency of benzannulated bicyclic compounds as interesting ligands. Herein the work was extended to a series of novel tricyclic compounds. Carboline- and phenothiazine-derivated compounds were designed and synthesized. In vitro competition binding assays for sigma 1 and 2 receptors showed that most of them have high affinity for sigma 1 receptor (Ki = 2.5-18 nM), and selectivity toward sigma 2 receptor, without cytotoxic effects on SY5Y cells.

Design, synthesis and biological evaluation of novel podophyllotoxin derivatives bearing 4β-disulfide/trisulfide bond as cytotoxic agents

A novel series of C-4β-disulfide/trisulfide-containing podophyllotoxin derivatives were designed, synthesized, and biologically evaluated for their cytotoxic activities against human cancer cell lines, including KB (Mouth Epidermal Carcinoma Cells) and KB/VCR (Vincristine-resistant Mouth Epidermal Carcinoma Cells). Most of these compounds exhibited promising moderate to good cytotoxic activities. In particular, some of them displayed even superior activities to that of etoposide, especially for KB/VCR cell lines, indicating that introduction of the disulfide/trisulfide moiety would be beneficial for overcoming the multi-drug resistant limitation of etoposide. Moreover, the metabolic evaluation of the most promising compound was further performed to reveal that disulfide bond can be stable in human plasma over 8 hours, indicating good potential of these compounds for in vivo anti-cancer activities.

NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF

The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.

Fluorinated non-imidazole histamine H3 receptor antagonists

Fluorine substituents have become a widespread and important component in drug design and development. Here, the synthesis of fluorine containing compounds and some corresponding precursor molecules are presented for potential isotope labelling as well as their data obtained with in vitro and in vivo screenings. The compounds vary in the basic centres (piperidine or pyrrolidine) and are fluoro substituted in different positions of the basic alicyclic moiety. Pharmacological evaluation resulted in ligands with high affinities at hH3 receptor in the nanomolar and subnanomolar concentration range and some with high antagonist in vivo potencies.

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide compounds corresponding to formula I processes for the preparation thereof, pharmaceutical compositions containing these compounds, and the use of such substituted sulfonamide compounds in pharmaceutical compositions for the treatment and/or inhibition of pain and other conditions at least partly mediated by the bradykinin 1 receptor

CHEMICAL PROCESS

The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline.

Synthesis and preliminary evaluation of novel analogues of quindolines as potential stabilisers of telomeric G-quadruplex DNA

Telomeric DNA is a potential selective target for cancer therapy since the tumour-associated enzyme telomerase regulates telomere maintenance in most cancer cells. The 3′ single-stranded ends of telomeric DNA can be folded into quadruplex structures by appropriate small molecules. We describe the preparation of a new class of 2,7-disubstituted 10H-indolo[3,2-b]quinolines with enhanced selectivity for the stabilisation of quadruplex DNA compared to duplex DNA, and also the preparation of a key intermediate for the synthesis of trisubstituted quindolines.

3- Or 4-monosubstituted phenol derivatives useful as H3 ligands

The invention relates to 3- or 4-monosubstituted phenol derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.